These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33476722)

  • 1. Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism.
    Basolo A; Matrone A; Elisei R; Santini F
    Semin Cancer Biol; 2022 Feb; 79():197-202. PubMed ID: 33476722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis.
    Makita N; Iiri T
    Thyroid; 2013 Feb; 23(2):151-9. PubMed ID: 23398161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
    Sakurai K; Fukazawa H; Arihara Z; Yoshida K
    Tohoku J Exp Med; 2010 Sep; 222(1):39-44. PubMed ID: 20814176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders.
    Jannin A; Penel N; Ladsous M; Vantyghem MC; Do Cao C
    Crit Rev Oncol Hematol; 2019 Sep; 141():23-35. PubMed ID: 31202955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
    Sáez JM
    Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
    Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
    Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review.
    Illouz F; Laboureau-Soares S; Dubois S; Rohmer V; Rodien P
    Eur J Endocrinol; 2009 Mar; 160(3):331-6. PubMed ID: 19103722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
    Meng S; Wu H; Wang J; Qiu Q
    Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors.
    Illouz F; Braun D; Briet C; Schweizer U; Rodien P
    Eur J Endocrinol; 2014 Sep; 171(3):R91-9. PubMed ID: 24833135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target.
    Vetter ML; Kaul S; Iqbal N
    Endocr Pract; 2008; 14(5):618-24. PubMed ID: 18753108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
    Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
    Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients.
    Lechner MG; Vyas CM; Hamnvik OR; Alexander EK; Larsen PR; Choueiri TK; Angell TE
    Thyroid; 2018 Apr; 28(4):437-444. PubMed ID: 29652599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid dysfunction from antineoplastic agents.
    Hamnvik OP; Larsen PR; Marqusee E
    J Natl Cancer Inst; 2011 Nov; 103(21):1572-87. PubMed ID: 22010182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
    Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current evidence on thyroid related adverse events in patients treated with protein tyrosine kinase inhibitors.
    Gabora K; Piciu A; Bădulescu IC; Larg MI; Stoian IA; Piciu D
    Drug Metab Rev; 2019 Nov; 51(4):562-569. PubMed ID: 31718371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.
    Wang Z; Wang H; Bu C; Meng B; Mu Y; Gao S; Chen W; Tao X
    Eur J Clin Pharmacol; 2024 Jun; 80(6):827-838. PubMed ID: 38483545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Bailey EB; Tantravahi SK; Poole A; Agarwal AM; Straubhar AM; Batten JA; Patel SB; Wells CE; Stenehjem DD; Agarwal N
    Clin Genitourin Cancer; 2015 Jun; 13(3):e131-7. PubMed ID: 25497584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.
    Ye L; Santarpia L; Gagel RF
    Endocr Rev; 2010 Aug; 31(4):578-99. PubMed ID: 20605972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.
    De Falco V; Carlomagno F; Li HY; Santoro M
    Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):307-318. PubMed ID: 28911727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert opinion on thyroid complications of new anti-cancer therapies: Tyrosine kinase inhibitors.
    Drui D; Illouz F; Do Cao C; Caron P
    Ann Endocrinol (Paris); 2018 Oct; 79(5):569-573. PubMed ID: 30126626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.